Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Phase 3

Recruiting

• Conditions: Treatment Resistant Depression
• Interventions: Drug: Psilocybin

• Registration Number: NCT05711940
• Lead Sponsor: COMPASS Pathways

Brief Summary

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Detailed Description

This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD.

Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg.

The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period.

Part A will include a nine-week follow-up from initial investigational product (IP) administration.

Part B will include a further 17 weeks follow-up out to 26 weeks from initial IP administration.

Part C will include a further 26 weeks follow-up out to 52 weeks from initial IP administration.

In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.

Study Timeline

• Study First Submitted: 2023-01-25
• Study First Submitted QC: 2023-01-25
• Study First Posted: 2023-02-03
• Study Start: 2023-02-14
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-19
• Last Update Posted: 2025-08-20
• Primary Completion: 2026-02
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 568

Inclusion Criteria

1. Aged ≥18 years at Screening
2. Major depression without psychotic features (single or recurrent episode as informed by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition [DSM-5])
3. If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening
4. MADRS total score ≥20 at Screening and Baseline to ensure at least moderate severity of depression
5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and using the supplementary advice on additional antidepressants not included in MGH-ATRQ
6. At Screening, agreement to discontinue all prohibited medications

Key

Exclusion Criteria

1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)
2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity based on medical history and clinical judgement
3. Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module
4. Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)
5. Psychiatric inpatient within the past 12 months prior to Screening
6. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode
7. Transcranial magnetic stimulation within the past six months prior to Screening
8. Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 30 days prior to Screening
9. Exposure to COMP360 psilocybin therapy prior to Screening

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
25 mg COMP360 Psilocybin	Psilocybin	25 mg COMP360 Psilocybin
10 mg COMP360 Psilocybin	Psilocybin	10 mg COMP360 Psilocybin
1 mg COMP360 Psilocybin	Psilocybin	1 mg COMP360 Psilocybin, active comparator

Primary Outcome Measures

Name	Time	Method
COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score.	Week 6	Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity

Secondary Outcome Measures

Name	Time	Method
COMP360 25 mg versus COMP360 10 mg for the change from baseline in MADRS total score.	Week 6	Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity
COMP360 25 mg versus COMP360 1 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.	Week 6	Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.
COMP360 25 mg versus COMP360 10 mg for the change from baseline in Sheehan Disability Scale (SDS) total score.	Week 6	Sheehan Disability Scale (SDS) is a brief, five-item self report inventory that assesses functional impairment in work/school, social life, and family life.

Trial Locations

Locations (116)

Lighthouse Psychiatry Scottsdale; 🇺🇸 Gilbert, Arizona, United States

Clinical Innovations, Inc.; 🇺🇸 Bellflower, California, United States

M3 Wake Research; 🇺🇸 Encino, California, United States

The Regents of the University of California - San Diego; 🇺🇸 La Jolla, California, United States

Kadima Neuropsychiatry Institute; 🇺🇸 La Jolla, California, United States

CalNeuro Research Group, Inc; 🇺🇸 Los Angeles, California, United States

Catalina Research Institute, LLC; 🇺🇸 Montclair, California, United States

Piedmont Hospital Neuroscience Centre; 🇺🇸 Oakland, California, United States

ATP Clinical Research, Inc.; 🇺🇸 Orange, California, United States

CITrials; 🇺🇸 Riverside, California, United States

Scroll for more (106 remaining)